Research article · 14 Apr 2026
Conference abstractPublished 2 Nov 2016
A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication
University of Hong Kong, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objectives: The conserved residues 318-483 in the PB2 subunit of influenza A polymerase is an independently folded cap-binding domain (PB2cap) that exhibits a distinct binding mode from other host cap-binding proteins, which suggests that PB2cap might be an ideal drug target. This study aimed to identify a new class of anti-influenza inhibitors that specifically disrupts the interaction between PB2cap and host cap structures. Methods: An innovative fluorescence polarization assay was established for primary screening, followed by cap-binding inhibitory activity, antiviral efficacy and cytotoxicity evaluations of the selected compounds. The best compound was characterized by multicycle virus growth assay, cross-protection test, synergism evaluation, mini-replicon assay, binding affinity analysis, docking simulation and mouse study. Results: Several PB2 cap-binding inhibitors were discovered. The compound 7-(4-hydroxy-2-oxo-2H-chromen-3-yl)-6H,7H,8Hchromeno[ 3âÂ?Â?,4âÂ?Â?:5,6]pyrano[3,2-c]chromene-6,8-dione, designated PB2-39, was identified as a potent inhibitor of replication of multiple subtypes of influenza A virus, including H1N1, H3N2, H5N1, H7N7, H7N9 and H9N2 in vitro and H1N1, H5N1 and H7N9 in vivo. Combinational treatment with the influenza virus release inhibitor zanamivir and PB2-39 exerted a synergistic anti-influenza effect. Mechanistic experiments supported that PB2-39 suppressed viral polymerase activity. Docking and binding affinity analyses demonstrated that PB2-39 interacted with the PB2 cap-binding pocket, suggesting its role as a cap-binding competitor. Conclusions: Our study provides new insights for the strategic development of novel cap-binding inhibitors of influenza A viruses.
Subjects
Infectious DiseasesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Infectious Diseases & Therapy.
Research article · 5 May 2025
The Ultimate Cure for the COVID Syndemic
Mini review · 29 Apr 2025
COVID-19 Systematic Mini-Review as of April 2025
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Infectious Diseases & Therapy
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Yuan Shuofeng”
